Ranked by engagement
Top topics — all time page 25
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 25 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: A newcomer's list of things that confused me, and the fixes
Posting this under the heading it deserves: A newcomer's list of things that confused me, and the fixes Everything below is what sits behind that. Question in the title. Context below, and I have tried to…
|
+4 | 8 | 57k | 23d |
|
Spreadsheets: an appreciation
On the subject in the title: Spreadsheets: an appreciation Working notes rather than a conclusion. Lower-stakes topic, but the sourcing rule still applies if anyone makes a claim. Something adjacent that I…
|
+26 | 30 | 25k | 2.1y |
|
Second pass at: A pooled estimate that changed when one trial was added
On the subject in the title: Second pass at: A pooled estimate that changed when one trial was added Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
+26 | 30 | 22k | 1mo |
|
Athletes in weight-category sports: a different risk calculus — a second dataset
On the subject in the title: Athletes in weight-category sports: a different risk calculus — a second dataset Working notes rather than a conclusion. General question, not a request for advice about my own…
|
+37 | 41 | 16k | 20mo |
|
Meeting a protein target on a suppressed appetite
Meeting a protein target on a suppressed appetite Writing it up because I had to work it out twice and would rather nobody else did. Longitudinal report with the method stated, because a number without a…
|
+39 | 44 | 11k | 7mo |
|
Second pass at: What pooling buys you and what it destroys
Posting this under the heading it deserves: Second pass at: What pooling buys you and what it destroys Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of a claim…
|
+32 | 36 | 19k | 4mo |
|
Revisiting: Aggregates and why a purity assay may miss them entirely
Posting this under the heading it deserves: Revisiting: Aggregates and why a purity assay may miss them entirely Everything below is what sits behind that. I would like to understand what this number means…
|
+48 | 53 | 918 | 8mo |
|
Revisiting: Patterns that reliably precede a problem, documented
Posting this under the heading it deserves: Revisiting: Patterns that reliably precede a problem, documented Everything below is what sits behind that. A logistics question, since the answers here are usually…
|
+16 | 20 | 36k | 2mo |
|
Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…
|
+18 | 22 | 37k | 8mo |
|
MS/MS sequence confirmation: what it costs and when it is worth it — what changed since
Posting this under the heading it deserves: MS/MS sequence confirmation: what it costs and when it is worth it — what changed since Everything below is what sits behind that. Working through the identity…
|
+34 | 39 | 21k | 1mo |
|
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…
|
+6 | 10 | 51k | 13mo |
|
Refrigerated versus room temperature: the trade-off stated plainly
Refrigerated versus room temperature: the trade-off stated plainly Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have…
|
2 | 66k | 2y | |
|
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
+41 | 46 | 1.2k | 4mo |
|
Coming back to: The nausea timeline across the first four weeks, with a tabulated log
Posting this under the heading it deserves: The nausea timeline across the first four weeks, with a tabulated log Everything below is what sits behind that. Reporting something rather than asking about it, in…
|
+42 | 49 | 576 | 17mo |
|
Revisiting: Why I ask for the gradient before I discuss the number
Posting this under the heading it deserves: Revisiting: Why I ask for the gradient before I discuss the number Everything below is what sits behind that. I would like to understand what this number means…
|
+15 | 19 | 43k | 10mo |
|
Dose numbers for oral formulations are not comparable to injectable ones
On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…
|
+19 | 23 | 39k | 6mo |
|
Coverage in the US: a map of the usual obstacles
Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the…
|
+46 | 50 | 7.9k | 5mo |
|
Follow-up: Signs of dehydration worth acting on
Posting this under the heading it deserves: Signs of dehydration worth acting on Everything below is what sits behind that. General question, not a request for advice about my own care — I know the difference…
|
+35 | 39 | 9.8k | 1d |
|
[2026 update] Reading a supplementary appendix and finding the interesting part
On the subject in the title: Reading a supplementary appendix and finding the interesting part Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024)…
|
+39 | 44 | 8.2k | 5mo |
|
Second pass at: Programming during a large energy deficit
Posting this under the heading it deserves: Second pass at: Programming during a large energy deficit Everything below is what sits behind that. Longitudinal report with the method stated, because a number…
|
+44 | 48 | 632 | 30d |
|
Second pass at: Where impurities in solid-phase peptide synthesis come from
Posting this under the heading it deserves: Second pass at: Where impurities in solid-phase peptide synthesis come from Everything below is what sits behind that. A documentation question rather than an…
|
+47 | 51 | 3.3k | 5mo |
|
Second pass at: The storage lookup and where its data comes from
On the subject in the title: Second pass at: The storage lookup and where its data comes from Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a…
|
+38 | 42 | 13k | 19d |
|
Buffers, pH and why a formulation is a formulation
Buffers, pH and why a formulation is a formulation Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the first three replies will…
|
+11 | 15 | 51k | 21mo |
|
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…
|
+44 | 48 | 3k | 10mo |
|
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…
|
2 | 65k | 10mo | |
|
Second pass at: Coverage in the US: a map of the usual obstacles
On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
4 | 62k | 9mo | |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
2 | 63k | 5mo | |
|
Impurity thresholds: where the common numbers come from — what changed since
Posting this under the heading it deserves: Impurity thresholds: where the common numbers come from — what changed since Everything below is what sits behind that. A documentation question rather than an…
|
2 | 61k | 3mo | |
|
Why oral semaglutide needs an absorption enhancer at all — what changed since
Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
2 | 61k | 14mo | |
|
Racemisation and why it is invisible to a mass measurement — what changed since
Racemisation and why it is invisible to a mass measurement — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I…
|
+11 | 15 | 42k | 16d |